Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Molecular Medicine,Physiology
Reference15 articles.
1. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B;Nurmohamed;J. Am. Coll. Cardiol.,2021
2. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein;Ridker;N. Engl. J. Med.,2008
3. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients;Nissen;JAMA,2023
4. Inflammation in atherosclerosis – no longer a theory;Libby;Clin. Chem.,2021
5. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N. Engl. J. Med.,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Simultaneously blocking ANGPTL3 and IL-1β for the treatment of atherosclerosis through lipid-lowering and anti-inflammation;Inflammation Research;2024-09-10
2. Neuroimmune circuits in the plaque and bone marrow regulate atherosclerosis;Cardiovascular Research;2024-08-01
3. Association between pan-immune-inflammation value and hyperlipidemia in the United States population;2024-07-23
4. Measuring and Targeting Persistent Inflammation in Chronic Coronary Disease;JACC: Advances;2024-07
5. Inflammatory risk and clinical outcomes according to polyvascular atherosclerotic disease status in patients undergoing PCI;Clinical Research in Cardiology;2024-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3